5月13日，辽宁省委省政府对在2024年辽宁全面振兴新突破三年行动攻坚之年作出突出贡献的241户企业予以 通报表扬，何氏眼科（301103）连续第二年荣获此殊荣。 2024年以来，扎根辽宁30年的何氏眼科以科技创新蓄势赋能，增强发展实力，提升服务能力，推动眼健康服 务向智能化、精准化和普惠化转型，助力健康辽宁和数字辽宁建设。 何氏眼科围绕"健康中国"战略和全球眼健康总体方向，以构建"智慧光明城"为战略目标，发挥独有的眼健康 全产业链生态平台优势，借助大数据、人工智能、基因、干细胞等新技术，通过精准医疗和智慧医疗赋能， 加快发展新质生产力，全面开启数字化、全方位、全场景、全生命周期眼健康管理的服务新模式，不断满足 人民群众多层次多样化眼健康和大健康需求。 为切实提高儿童青少年视力健康水平，作为辽宁省青少年近视防控基地，何氏眼科通过科技创新和模式探 索，构建了辽宁特色的"365近视防控体系"。 此外，何氏眼科将数字技术、人工智能与公益相结合，专业医疗技术和百姓需求相结合，持续在辽宁全省范 围内搭建布局广泛的基层眼科医疗服务网络。公司实施的"光明小屋"项目在2024年全国首届社会办医"新质生 产力"案例大赛中荣膺服 ...

Group 1: Mergers and Acquisitions Strategy - The company adheres to a cautious and prudent investment principle when selecting merger targets, focusing on strategic alignment, compliance, value assessment, and acquisition methods [2][3][7] - The company aims to acquire medical targets in the ophthalmology consumer healthcare sector and upstream/downstream industry chain extensions [7][8] Group 2: Research and Development Investments - In 2024, the company increased R&D investments significantly, focusing on AI-assisted diagnosis and new intelligent devices, which are expected to enhance diagnostic efficiency and service capabilities [4][8][17] - The company achieved a post-operative satisfaction rate of over 98% through advanced equipment and innovative surgical techniques [3][4] Group 3: Financial Performance - The company reported a net profit of -27.4 million yuan in 2024, with a net profit margin of -3.22%, attributed to intensified industry competition and changes in medical insurance payment methods [8][9] - In Q1 2025, the company achieved a net profit of 32.5 million yuan, with a net profit margin of 11.16%, indicating a recovery compared to the previous year [8] Group 4: Internet Healthcare Development - The company's online healthcare platform has over 900,000 users and 120 online doctors, providing a range of services including consultations and health management [6][8] Group 5: Market Competition and Product Development - The company focuses on differentiated technology and customized products, such as the "Zhaoxing lens" and the "365 Myopia Prevention System," to strengthen its market position in vision care [9][10] - The company is actively monitoring advancements in gene therapy and AI-assisted surgical planning to maintain its competitive edge [8][9] Group 6: Social Responsibility and ESG Initiatives - The company has trained over 50,000 grassroots doctors and healthcare managers, contributing to public health and eye care accessibility [23][24] - The company integrates ESG principles into its operations, focusing on sustainable development and community health initiatives [25][26]

Core Viewpoint - He Eye Hospital has officially launched the "EVO ICL Intraocular Lens Specialty Outpatient Clinic," marking an upgrade in the refined management of refractive services [1] Group 1: Company Developments - He Eye Hospital will collaborate with STAAR Surgical to establish "EVO ICL Project Demonstration Centers" in Shenyang and Dalian, and a "EVO ICL Clinical Cooperation Center" in Anshan, creating a precise diagnosis and treatment network in Liaoning [1] - The company aims to standardize the training system for refractive talent and accelerate the promotion of innovative technologies and treatment concepts, providing personalized visual quality solutions with unified technical standards and regulated treatment processes [1] Group 2: Market Insights - China, as the country with the largest population of myopia, has a significant demand for refractive surgery, with the refractive surgery market expected to grow from 5.9 billion yuan in 2015 to 72.5 billion yuan by 2025, representing a compound annual growth rate of 28.51% [1] - The continuous breakthroughs in refractive surgery technology are crucial for improving the quality of life for adults with myopia, enhancing convenience in sports and work, and expanding career development opportunities for young people [1] Group 3: Technological Advancements - ICL implantation surgery is highlighted as a major breakthrough in myopia correction, offering unique advantages such as reversibility, a wide correction range, enhanced night vision, and UV protection, providing safer and more precise solutions for patients [2] - He Eye Hospital has been engaged in refractive services for nearly 30 years, leveraging its expert team and focusing on technological innovation, academic leadership, and service models to continuously upgrade surgical techniques [2] - The AI-driven personalized femtosecond surgery utilizes AI technology to accurately obtain corneal aberration data, creating visualized personalized models and showcasing different aberration optimization schemes, thus meeting diverse patient needs and initiating a new transformation in AI-driven surgical procedures [2]

本报讯 （记者李勇）4月25日，辽宁何氏眼科医院集团股份有限公司（以下简称"何氏眼科"）发布《2024年环境、社会和 公司治理（ESG）报告》，从多个维度全面展示过去一年公司在ESG领域的布局与实践成果，以及在打造"智慧光明城"，推动 可持续发展道路上的坚定决心与积极作为。 （编辑 张伟） 自创立以来，何氏眼科始终以科技创新为引领，秉持"奉献社会、百姓信赖、创新引领、共创幸福"的核心价值观和"科技 人文"的经营理念，坚持"预防为主、防治结合"的服务理念，依托创新技术和专业人才，为各类眼病患者提供眼科全方位诊疗 服务。公司在白内障、青光眼、玻璃体视网膜病变、干眼症、中医眼科、屈光不正等诊疗领域积累了丰富的临床经验和技术优 势。 报告显示，何氏眼科围绕"健康中国"战略方向和全球眼健康总体方向，以构建"智慧光明城"为战略目标，积极推进医疗健 康产业线上线下融合布局。依托独有的眼健康全产业链生态平台优势，借助大数据、人工智能、基因技术、干细胞技术等创新 手段，通过精准医疗和智慧医疗赋能，为患者提供数字化、全方位、全场景、全生命周期的眼健康管理服务新模式。公司坚持 以人为本，注重激发员工潜能与归属感，打造安全、公平、关 ...

Core Viewpoint - He Eye Hospital demonstrates a strong commitment to sustainable development and the creation of a "Smart Bright City" through its comprehensive ESG report for 2024, showcasing its achievements and strategic direction in the past year [1] Group 1: Technological Innovation and Service Model - He Eye Hospital has consistently prioritized technological innovation, adhering to its core values of social contribution, public trust, and collaborative happiness, while focusing on a service model that emphasizes prevention and treatment [2] - The hospital aims to integrate online and offline healthcare services, leveraging its unique eye health ecosystem and advanced technologies such as big data, artificial intelligence, and stem cell technology to provide comprehensive eye health management [2] Group 2: Talent Development and Employment - The company emphasizes a people-oriented approach, fostering employee potential and creating a supportive work environment, while continuously improving its management system in areas such as employee rights, career growth, and health safety [3] - He Eye Hospital collaborates with various medical universities to cultivate high-quality talent in fields such as ophthalmology and public health, addressing future strategic needs [3] Group 3: Customer Focus and Service Quality - The hospital is dedicated to enhancing product quality and customer service experience, implementing a comprehensive service management system that covers all stages of patient care [4] - He Eye Hospital has established a dedicated customer service department to standardize service processes and improve customer satisfaction through meticulous management [4] Group 4: Social Responsibility and Public Welfare - He Eye Hospital aims for a vision of "No Blindness" and aligns its goals with the "Healthy China" strategy and UN sustainable development objectives, actively engaging in public welfare initiatives and education [5] - The establishment of training bases has positioned the hospital as a key player in domestic and international ophthalmology training, contributing to the overall improvement of the eye care industry [5] Group 5: Governance and Environmental Responsibility - The company emphasizes strong governance as a foundation for sustainable development, focusing on risk management and timely information disclosure [6] - He Eye Hospital integrates environmental management into its operations, implementing measures to reduce ecological impact and promote green practices [6] - The chairman expresses a commitment to technological innovation and long-term goals, aiming to benefit public health and contribute to global eye health initiatives [6]

一、重要提示 本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者 应当到证监会指定媒体仔细阅读年度报告全文。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：301103 证券简称：何氏眼科 公告编号：2025-006 辽宁何氏眼科医院集团股份有限公司2024年年度报告摘要 □适用 √不适用 公司上市时未盈利且目前未实现盈利 □适用 √不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 √适用 □不适用 所有董事均已出席了审议本报告的董事会会议。 容诚会计师事务所（特殊普通合伙）对本年度公司财务报告的审计意见为：标准的无保留意见。 本报告期会计师事务所变更情况：公司本年度会计师事务所由变更为容诚会计师事务所（特殊普通合 伙）。 非标准审计意见提示 1、公司主营业务及产品 公司坚持科技创新，为客户提供个性化、智慧化的眼健康管理服务。针对用户当前的眼健康需求，公司 依托先进医疗技术、人才、诊疗设备，为各类眼病患者提供眼科全科诊疗服务，诊疗服务中除了诊治常 公司经本次董事会审议通过的利润分配预案为：以155,303,752股为基数，向全体股东每10股派发现 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 二、通过深交所交易系统投票的程序 1. 投票的时间：2025年5月22日的交易时间，即上午9:15－9:25，9:30－11:30和13:00-15:00 2. 股东可以登录证券公司交易客户端通过交易系统投票。 三、通过深交所互联网投票系统的投票程序 1. 投票时间：2025年5月22日9:15-15:00 2. 股东通过互联网投票系统进行网络投票，需按照《深圳证券交易所投资者网络服务身份认证业务指 引》的规定办理身份认证，取得"深交所数字证书"或"深交所投资者服务密码"。具体身份认证流程可登 录互联网投票系统http://wltp.cninfo.com.cn规则指引栏目查阅。 3. 股东根据获取的服务密码或数字证书，可登录http://wltp.cninfo.com.cn在规定时间内通过深交所互联 网投票系统进行投票。 附件2 辽宁何氏眼科医院集团股份有限公司 2024年年度股东大会授权委托书 辽宁何氏眼科医院集团股份有限公司： 兹委托 先生/女士代表本人/本公司出席辽宁何氏眼科医院集团股份有限公司2024年年度股东大会并代为 行使表决权。授权期限自委托书签 ...

辽宁何氏眼科医院集团股份有限公司 未来三年（2025 年-2027 年）股东分红回报规划 为完善和健全辽宁何氏眼科医院集团股份有限公司（以下简称公司）股东回 报和利润分配政策，建立持续、稳定、科学的利润分配机制，引导投资者树立长 期投资和理性投资理念，根据中国证券监督管理委员会《关于进一步落实上市公 司现金分红有关事项的通知》《上市公司监管指引第 3 号——上市公司现金分红》 等相关规定，结合公司实际情况和未来发展需要，公司制定了《辽宁何氏眼科医 院集团股份有限公司未来三年（2025 年-2027 年）股东分红回报规划》，具体如 下： 一、股东回报规划考虑的因素 公司着眼于长远和可持续发展，在综合分析企业发展战略、社会资金成本、 外部融资环境等因素的基础上，充分考虑公司目前及未来盈利规模、现金流量状 况、发展所处阶段、项目投资资金需求、银行信贷等情况，平衡股东的短期利益 和长期利益，对利润分配作出制度性安排，从而建立对投资者持续、稳定、科学 的分红回报机制，以保证公司利润分配政策的连续性和稳定性。 二、股东回报规划的制定原则 （四）公司实行现金分红的条件 满足以下条件的，公司应当进行现金分配，且每年以现金方式 ...

一、资质条件 1.基本信息 辽宁何氏眼科医院集团股份有限公司 2024 年年审会计师履职情况评估报告 辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）聘请容诚会计师事 务所（特殊普通合伙）（以下简称"容诚所"）作为公司 2024 年度年报审计师。根 据财政部、国资委及证监会颁布的《国有企业、上市公司选聘会计师事务所管理 办法》，公司对容诚所在近一年审计中的履职情况进行了评估。经评估，公司认 为，近一年容诚所资质等方面合规有效，履职能够保持独立性，勤勉尽责，公允 表达意见。具体情况如下。 容诚会计师事务所（特殊普通合伙）由原华普天健会计师事务所（特殊普通 合伙）更名而来，初始成立于 1988 年 8 月，2013 年 12 月 10 日改制为特殊普通 合伙企业，是国内最早获准从事证券服务业务的会计师事务所之一，长期从事证 券服务业务。注册地址为北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26，首席合伙人刘维。 2.人员信息 截至 2024 年 12 月 31 日，容诚会计师事务所共有合伙人 212 人，共有注册 会计师 1552 人，其中 781 人签署过证券服务业务审 ...

证券代码：301103 证券简称：何氏眼科 公告编号：2025-009 辽宁何氏眼科医院集团股份有限公司 2024年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 根据《上市公司监管指引第 2 号—上市公司募集资金管理和使用的监管要求》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 及《深圳证券交易所创业板上市公司自律监管指南第 2 号——公告格式》等规定， 将辽宁何氏眼科医院集团股份有限公司（以下简称公司）2024 年度募集资金存 放与使用情况报告如下： 一、募集资金基本情况 （一）募集资金金额和到账时间 经中国证券监督管理委员会《关于同意辽宁何氏眼科医院集团股份有限公司 首次公开发行股票注册的批复》（证监许可【2022】126号）同意注册，公司首 次公开发行人民币普通股（A股）3,050.00万股，每股面值1元，每股发行价格为 人民币42.50元，募集资金总额为人民币129,625.00万元，扣除与本次发行有关的 费用后募集资金净额为人民币116,431.13万元。上述募集资金于2022年3 ...